Risk Factors for Rebleeding after Endoscopic Selective Variceal Devascularization in Patients with Hepatitis B Cirrhosis and Acute Variceal Bleeding
MA Jiali,JIANG Yu,HU Julong,AI Zhenglin,HE Lingling,ZHOU Yuling,LIANG Xiuxia,LIN Yijun,WEI Hongshan,LI Ping
DOI: https://doi.org/10.3969/j.issn.1001-5256.2021.11.017
2021-01-01
Abstract:ObjectiveTo investigate the rebleeding rate after endoscopic selective variceal devascularization (ESVD) and the predictive factors for rebleeding in patients with hepatitis B cirrhosis and esophageal variceal bleeding (EVB). MethodsThe patients with hepatitis B cirrhosis and EVB who attended Beijing Ditan Hospital, Capital Medical University, from October 2010 to December 2019 and underwent ESVD for the first time were enrolled, and a total of 442 patients were screened out based on inclusion and exclusion criteria. Routine clinical indices, laboratory markers, imaging findings, and endoscopic findings were compared between patients, and the patients were followed up to observe rebleeding. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier method was used to describe rebleeding and survival status, and a Cox regression analysis was used to determine the independent risk factors for variceal rebleeding. ResultsThe 1-, 2-, 3-, 4-, and 5-year cumulative rebleeding rates after first ESVD treatment were 25.11%, 33.94%, 39.82%, 42.08%, and 45.02%, respectively. The univariate analysis showed that age, systolic pressure, duration of antiviral therapy ≥1 year, ascites, white blood cell count, neutrophil, and direct bilirubin were associated with rebleeding (all P＜0.05), and the multivariate analysis showed that duration of antiviral therapy ≥1 year (hazard ratio ［HR］=0.504, 95% confidence interval ［CI］: 0.357-0.711, P＜0.001) and ascites (HR=1.424, 95%CI: 1.184-1.714, P＜0.001) were independent influencing factors for variceal rebleeding. ConclusionESVD has a low rebleeding rate in the treatment of hepatitis B cirrhosis with EVB, and presence of ascites and a short duration of antiviral therapy are independent risk factors for rebleeding after treatment.